Click for best price
Postpemic Era Molecular Diagnostics NAT Market Size, Share 2022
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
Global Molecular Diagnostics and NAT Market Segment Research Report 2022?, which aims to sort out the development status and trends of the Molecular Diagnostics and NAT industry at home and abroad, estimate the overall market scale of the Molecular Diagnostics and NAT industry and the market share of major countries, Molecular Diagnostics and NAT industry, and study and judge the downstream market demand of Molecular Diagnostics and NAT through systematic research, Analyze the competition pattern of Molecular Diagnostics and NAT, so as to help solve the pain points of various stakeholders in Molecular Diagnostics and NAT industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Molecular Diagnostics and NAT Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Molecular Diagnostics and NAT Market?
Roche
Abbott
BD
Biomerieux
Qiagen
Thermo Fisher Scientific
Agilent
GenMark
Siemens Healthcare
AutoGenomics
Major Type of Molecular Diagnostics and NAT Covered in XYZResearch report:
Amplification Technologies
Amplified Gene Detection Technologies
DNA And Oligonucleotide Microarrays
Gene Sequencing
Application Segments Covered in XYZResearch Market
Hospitals and Clinics
Research Institutes
Diagnostic Centers
For any other requirements, please feel free to contact us and we will provide you customized report.
| Report Attributes |
Report Details |
| Report Title |
(Post-pandemic Era)-Global Molecular Diagnostics and NAT Market Segment Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
86 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
Global Molecular Diagnostics and NAT Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Molecular Diagnostics and NAT Market by Value
2.2.1 Global Molecular Diagnostics and NAT Revenue by Type
2.2.2 Global Molecular Diagnostics and NAT Market by Value
2.3 Global Molecular Diagnostics and NAT Market by Sales
2.3.1 Global Molecular Diagnostics and NAT Sales by Type
2.3.2 Global Molecular Diagnostics and NAT Market by Sales
3. The Major Driver of Molecular Diagnostics and NAT Industry
3.1 Historical & Forecast Global Molecular Diagnostics and NAT Sales and Revenue (2018-2028)
3.2 Largest Application for Molecular Diagnostics and NAT (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Molecular Diagnostics and NAT Market
4.1 Regional Market Size in Terms of Sales (2022 & 2028)
4.2 Regional Market Share in Terms of Revenue (2022 & 2028)
4.3 Concentration Ratio (CR5& CR10) of Molecular Diagnostics and NAT Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Molecular Diagnostics and NAT Sales (2018-2028)
5.1 Current and Estimated Sales Breakdown by Type (2018-2028)
5.2 Current and Estimated Sales Breakdown by Application (2018-2028)
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Molecular Diagnostics and NAT Sales (2018-2028)
6.1 Current and Estimated Sales Breakdown by Type (2018-2028)
6.2 Current and Estimated Sales Breakdown by Application (2018-2028)
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Molecular Diagnostics and NAT Sales (2018-2028)
7.1 Current and Estimated Sales Breakdown by Type (2018-2028)
7.2 Current and Estimated Sales Breakdown by Application (2018-2028)
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Molecular Diagnostics and NAT Sales (2018-2028)
8.1 Current and Estimated Sales Breakdown by Type (2018-2028)
8.2 Current and Estimated Sales Breakdown by Application (2018-2028)
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Molecular Diagnostics and NAT Sales (2018-2028)
9.1 Current and Estimated Sales Breakdown by Type (2018-2028)
9.2 Current and Estimated Sales Breakdown by Application (2018-2028)
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Molecular Diagnostics and NAT Sales (2018-2028)
10.1 Current and Estimated Sales Breakdown by Type (2018-2028)
10.2 Current and Estimated Sales Breakdown by Application (2018-2028)
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Molecular Diagnostics and NAT Sales (2018-2028)
11.1 Current and Estimated Sales Breakdown by Type (2018-2028)
11.2 Current and Estimated Sales Breakdown by Application (2018-2028)
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. South America Molecular Diagnostics and NAT Sales (2018-2028)
12.1 Current and Estimated Sales Breakdown by Type (2018-2028)
12.2 Current and Estimated Sales Breakdown by Application (2018-2028)
12.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
12.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
13. Global Molecular Diagnostics and NAT Average Price Trend
13.1 Market Price for Each Type of Molecular Diagnostics and NAT in US (2018-2022)
13.2 Market Price for Each Type of Molecular Diagnostics and NAT in Europe (2018-2022)
13.3 Market Price for Each Type of Molecular Diagnostics and NAT in China (2018-2022)
13.4 Market Price for Each Type of Molecular Diagnostics and NAT in Japan (2018-2022)
13.5 Market Price for Each Type of Molecular Diagnostics and NAT in India (2018-2022)
13.6 Market Price for Each Type of Molecular Diagnostics and NAT in Korea (2018-2022)
13.7 Market Price for Each Type of Molecular Diagnostics and NAT in Southeast Asia (2018-2022)
13.8 Market Price for Each Type of Molecular Diagnostics and NAT in South America (2018-2022)
14. Industrial Chain (Impact of COVID-19)
14.1 Molecular Diagnostics and NAT Industrial Chain Analysis
14.2 Downstream
14.3 Impact of COVID-19
14.4 Post-pandemic Era
14.5 Technology Trends of Molecular Diagnostics and NAT
15. Molecular Diagnostics and NAT Competitive Landscape
15.1 Roche
15.1.1 Roche Company Profiles
15.1.2 Roche Product Introduction
15.1.3 Roche Molecular Diagnostics and NAT Sales, Revenue (2018-2022)
15.1.4 Strategic initiatives
15.2 Abbott
15.2.1 Abbott Company Profiles
15.2.2 Abbott Product Introduction
15.2.3 Abbott Molecular Diagnostics and NAT Sales, Revenue (2018-2022)
15.2.4 Strategic initiatives
15.3 BD
15.3.1 BD Company Profiles
15.3.2 BD Product Introduction
15.3.3 BD Molecular Diagnostics and NAT Sales, Revenue (2018-2022)
15.3.4 Strategic initiatives
15.4 Biomerieux
15.4.1 Biomerieux Company Profiles
15.4.2 Biomerieux Product Introduction
15.4.3 Biomerieux Molecular Diagnostics and NAT Sales, Revenue (2018-2022)
15.4.4 Strategic initiatives
15.5 Qiagen
15.5.1 Qiagen Company Profiles
15.5.2 Qiagen Product Introduction
15.5.3 Qiagen Molecular Diagnostics and NAT Sales, Revenue (2018-2022)
15.5.4 Strategic initiatives
15.6 Thermo Fisher Scientific
15.6.1 Thermo Fisher Scientific Company Profiles
15.6.2 Thermo Fisher Scientific Product Introduction
15.6.3 Thermo Fisher Scientific Molecular Diagnostics and NAT Sales, Revenue (2018-2022)
15.6.4 Strategic initiatives
15.7 Agilent
15.7.1 Agilent Company Profiles
15.7.2 Agilent Product Introduction
15.7.3 Agilent Molecular Diagnostics and NAT Sales, Revenue (2018-2022)
15.7.4 Strategic initiatives
15.8 GenMark
15.8.1 GenMark Company Profiles
15.8.2 GenMark Product Introduction
15.8.3 GenMark Molecular Diagnostics and NAT Sales, Revenue (2018-2022)
15.8.4 Strategic initiatives
15.9 Siemens Healthcare
15.9.1 Siemens Healthcare Company Profiles
15.9.2 Siemens Healthcare Product Introduction
15.9.3 Siemens Healthcare Molecular Diagnostics and NAT Sales, Revenue (2018-2022)
15.9.4 Strategic initiatives
15.10 AutoGenomics
15.10.1 AutoGenomics Company Profiles
15.10.2 AutoGenomics Product Introduction
15.10.3 AutoGenomics Molecular Diagnostics and NAT Sales, Revenue (2018-2022)
15.10.4 Strategic initiatives
16. Conclusion
17. Methodology and Data Source
LIST OF TABLES & FIGURES
List of Tables and Figures
Figure 1. Total Sales by Application of Molecular Diagnostics and NAT Industry (Volume)
Figure 2. Molecular Diagnostics and NAT Sales by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2028)
Figure 4. The Top 10 and 5 Players Market Share by Molecular Diagnostics and NAT Revenue in 2022
Figure 5. US Molecular Diagnostics and NAT Sales (2018-2028)
Figure 6. Sales Breakdown by Type (%)
Figure 7. Sales Breakdown by Type (%)
Figure 8. Sales Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Molecular Diagnostics and NAT Sales (2018-2028)
Figure 12. Sales Breakdown by Type (%)
Figure 13. Sales Breakdown by Type (%)
Figure 14. Sales Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Molecular Diagnostics and NAT Sales (2018-2028)
Figure 18. Sales Breakdown by Type (%)
Figure 19. Sales Breakdown by Type (%)
Figure 20. Sales Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Molecular Diagnostics and NAT Sales (2018-2028)
Figure 25. Sales Breakdown by Type (%)
Figure 26. Sales Breakdown by Type (%)
Figure 27. Sales Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Molecular Diagnostics and NAT Sales (2018-2028)
Figure 31. Sales Breakdown by Type (%)
Figure 32. Sales Breakdown by Type (%)
Figure 33. Sales Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Molecular Diagnostics and NAT Sales (2018-2028)
Figure 37. Sales Breakdown by Type (%)
Figure 38. Sales Breakdown by Type (%)
Figure 39. Sales Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Molecular Diagnostics and NAT Sales (2018-2028)
Figure 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Figure 44. Sales Breakdown by Type (%)
Figure 45. Sales Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Molecular Diagnostics and NAT Revenue, by Type (Million USD) (2018-2028)
Table 4. Molecular Diagnostics and NAT Sales, by Type (K Unit) (2018-2028)
Table 5. Molecular Diagnostics and NAT Sales (K Unit) by Application (2018-2028)
Table 6. Molecular Diagnostics and NAT Sales (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Sales (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2028)
Table 10. Ranking of Global Top Molecular Diagnostics and NAT Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Molecular Diagnostics and NAT Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 13. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 14. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 15. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Molecular Diagnostics and NAT Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 19. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 20. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 21. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Molecular Diagnostics and NAT Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 25. Table Current and Estimated Sales Breakdown by Type
Table 26. Current and Estimated Sales Breakdown by Type
Table 27. Current and Estimated Sales Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Molecular Diagnostics and NAT Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 30. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 31. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 32. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Molecular Diagnostics and NAT Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 36. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 37. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 38. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Molecular Diagnostics and NAT Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 42. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 44. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Molecular Diagnostics and NAT Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 48. Table Current and Estimated Sales Breakdown by Type (2018-2028)
Table 49. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Molecular Diagnostics and NAT in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Molecular Diagnostics and NAT in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Molecular Diagnostics and NAT in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Molecular Diagnostics and NAT in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Molecular Diagnostics and NAT in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Molecular Diagnostics and NAT in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Molecular Diagnostics and NAT in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Roche Profiles
Table 61. Roche Molecular Diagnostics and NAT Product Introduction
Table 62. Roche Molecular Diagnostics and NAT Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. Roche Strategic initiatives
Table 64. Abbott Profiles
Table 65. Abbott Molecular Diagnostics and NAT Product Introduction
Table 66. Abbott Molecular Diagnostics and NAT Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. Abbott Strategic initiatives
Table 68. BD Profiles
Table 69. BD Molecular Diagnostics and NAT Product Introduction
Table 70. BD Molecular Diagnostics and NAT Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. BD Strategic initiatives
Table 72. Biomerieux Profiles
Table 73. Biomerieux Molecular Diagnostics and NAT Product Introduction
Table 74. Biomerieux Molecular Diagnostics and NAT Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. Biomerieux Strategic initiatives
Table 76. Qiagen Profiles
Table 77. Qiagen Molecular Diagnostics and NAT Product Introduction
Table 78. Qiagen Molecular Diagnostics and NAT Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. Qiagen Strategic initiatives
Table 80. Thermo Fisher Scientific Profiles
Table 81. Thermo Fisher Scientific Molecular Diagnostics and NAT Product Introduction
Table 82. Thermo Fisher Scientific Molecular Diagnostics and NAT Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. Thermo Fisher Scientific Strategic initiatives
Table 84. Agilent Profiles
Table 85. Agilent Molecular Diagnostics and NAT Product Introduction
Table 86. Agilent Molecular Diagnostics and NAT Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. Agilent Strategic initiatives
Table 88. GenMark Profiles
Table 89. GenMark Molecular Diagnostics and NAT Product Introduction
Table 90. GenMark Molecular Diagnostics and NAT Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. GenMark Strategic initiatives
Table 92. Siemens Healthcare Profiles
Table 93. Siemens Healthcare Molecular Diagnostics and NAT Product Introduction
Table 94. Siemens Healthcare Molecular Diagnostics and NAT Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. Siemens Healthcare Strategic initiatives
Table 97. AutoGenomics Profiles
Table 98. AutoGenomics Molecular Diagnostics and NAT Product Introduction
Table 99. AutoGenomics Molecular Diagnostics and NAT Sales (Unit), Revenue (Million USD) (2018-2022)
Table 100. AutoGenomics Strategic initiatives
